RxDoctor Payments Data

Jorge Konopka, MD

Family Medicine · Miramar, FLNPI 1316140262

Payments from drug & device makers

$4,607in general payments, 2019–2025

Across 114 payments — averaging $40.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Johnson & Johnson$472
  • Amgen$457
  • Boehringer Ingelheim$454
  • Lilly USA, LLC$374
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$242
  • plus $919 from 16 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,50498%
  • Education$882%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,607 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$15,790
Medicare patients
34
Services billed
350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide22$33,193
OzempicSemaglutide15$23,434
EliquisApixaban15$13,435
Atorvastatin Calcium148$991
Valsartan14$711
Losartan Potassium85$630
Rosuvastatin Calcium60$615
Levothyroxine Sodium45$390
Pantoprazole Sodium56$389
Gabapentin39$369
Metformin Hcl94$340
Omeprazole24$338
Fluticasone Propionate21$279
Alendronate Sodium32$261
Metoprolol Succinate35$254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$1,688$56,62737 claims
PfizerEliquis$84$13,43515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miramar

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →